Using Platelet-Rich Plasma to Treat Severe Dry Eye Syndrome
Efficacy of Restoration of Lacrimal Secretion After Injection of Platelet-Rich Plasma (PRP) Into the Lacrimal Gland in Severe Dry Eye Syndromes (ReLIPSSO)
This study is testing if injecting Platelet-Rich Plasma into the tear glands can help people with severe dry eye syndrome produce more tears and feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Site Principal Investigator) |
| Trial ID | NCT06831253 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of injecting Platelet-Rich Plasma (PRP) into the lacrimal gland to enhance tear production in patients suffering from severe dry eye syndrome due to aqueous deficiency. Participants will receive four PRP injections during the study period. The goal is to determine if this treatment can restore normal lacrimal secretion and alleviate symptoms associated with dry eye conditions.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with severe dry keratoconjunctivitis and meeting specific platelet and clotting factor standards.
Not a fit: Patients with significant fibrosis of the conjunctival portion of the lacrimal gland or complete stenosis of both lacrimal meatus in the treated eye may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from severe dry eye syndrome.
How similar studies have performed: While the use of Platelet-Rich Plasma in various medical fields has shown promise, this specific application in treating dry eye syndrome is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Platelet counts, and clotting factors in the standarts * Presenting with severe dry keratoconjunctivitis diagnosed by an ophthalmologist Exclusion Criteria: * Patients with significant fibrosis of the conjunctival portion of the lacrimal gland * Patients with complete stenosis of both lacrimal meatus in the treated eye
Where this trial is running
Nice, Site Principal Investigator
- CHU de Nice — Nice, Site Principal Investigator, France (Recruiting)
Study contacts
- Study coordinator: Doctor Jean Philippe GROSSE, Dr
- Email: causeret.m@chu-nice.fr
- Phone: 04.92.03.47.02
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.